L-DOPA-2,5,6-d3

• UNSPSC Description:

  L-DOPA-2,5,6-d3 is the deuterium labeled L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain[1][2][3].

• Target Antigen:

  Dopamine Receptor; Endogenous Metabolite

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  GPCR/G Protein;Metabolic Enzyme/Protease;Neuronal Signaling

• Field of Research:

  Neurological Disease

• Purity:

  99.95

• Solubility:

  H2O : 25 mg/mL (ultrasonic;warming;adjust pH to 1 with HCl;heat to 60°C)

• Smiles:

  C([C@@H](C(O)=O)N)C1=C(C(O)=C(O)C(=C1[2H])[2H])[2H]

• Molecular Weight:

  200.208

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Hyland K, et al. Aromatic L-amino acid decarboxylase deficiency: diagnostic methodology. Clin Chem. 1992 Dec;38(12):2405-10.|[3]Merims D, et al. Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson's disease. Parkinsonism Relat Disord. 2008;14(4):273-80. Epub 2007 Nov 7.|[4]Perez-Pardo P, et al. Additive Effects of Levodopa and a Neurorestorative Diet in a Mouse Model of Parkinson's Disease. Front Aging Neurosci. 2018 Aug 3;10:237.|[5]Park HJ, et al. Anti-allodynic effects of levodopa in neuropathic rats. Yonsei Med J. 2013 Mar 1;54(2):330-5.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  53587-29-4